Enterprise Value

-12.07M

Cash

31.28M

Avg Qtr Burn

-8.445M

Short % of Float

12.71%

Insider Ownership

3.58%

Institutional Own.

51.66%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Uproleselan (GMI-1271) Details
Acute myeloid leukemia, Cancer

Phase 3

Update

Phase 2/3

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

GMI-1687 Details
Sickle cell disease

Phase 1a

Data readout

Rivipansel (GMI-1070) Details
SCD (Sickle Cell Disease)

Failed

Discontinued

GMI-1359 Details
Breast cancer

Failed

Discontinued